ストックスクリーナーアプリを入手
1.14
0.88%
0.01
アフターアワーズ：
1.18
0.04
+3.51%
前日終値:
$1.13
開ける：
$1.17
24時間の取引高:
236.89K
Relative Volume:
1.19
時価総額：
$102.26M
収益：
-
当期純損益:
$-30.15M
株価収益率:
-1.2527
EPS:
-0.91
ネットキャッシュフロー:
$-31.63M
1週間 パフォーマンス:
+17.54%
1か月 パフォーマンス:
+38.79%
6か月 パフォーマンス:
+70.40%
1年 パフォーマンス:
-38.71%
1日の値動き範囲:
$1.14
$1.22
1週間の範囲:
$0.9767
$1.29
52週間の値動き範囲:
$0.49
$2.5899
Context Therapeutics Inc Stock (CNTX) Company Profile
名前
Context Therapeutics Inc
セクター
電話
267-225-7416
住所
2001 MARKET STREET, PHILADELPHIA
CNTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
1.14 | 101.37M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | 開始されました | Guggenheim | Buy |
| 2025-04-21 | 開始されました | William Blair | Outperform |
| 2025-01-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-11-25 | 開始されました | D. Boral Capital | Buy |
| 2024-05-16 | 開始されました | Piper Sandler | Overweight |
Context Therapeutics Inc (CNTX) 最新ニュース
Context Therapeutics to Showcase CT-95 Data at AACR 2025 - MSN
Institutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the most - Yahoo Finance
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.20 Consensus PT from Analysts - Defense World
Context Therapeutics Grants Stock Options to New Hire - MSN
Will Context Therapeutics Inc. see short term momentumJuly 2025 Short Interest & Fast Moving Stock Watchlists - newser.com
Context Therapeutics Inc. to Present Trial Progress and Preclinical Data at SITC 2025 Annual Meeting - Quiver Quantitative
Context Therapeutics Announces Poster Presentations at the - GlobeNewswire
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of ... - Caledonian Record
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - Stock Titan
Context Therapeutics Inc. stock momentum explainedWeekly Stock Analysis & Fast Momentum Stock Entry Tips - newser.com
Is it too late to sell Context Therapeutics Inc.2025 Winners & Losers & High Win Rate Trade Tips - newser.com
Context Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - MarketScreener
Developing predictive dashboards with Context Therapeutics Inc. dataJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
Can a trend reversal in Context Therapeutics Inc. lead to recoveryEarnings Growth Report & Verified Technical Signals - newser.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Context Therapeutics announces inducement grant under Nasdaq listing rule - MarketScreener
GlobeNewswire by Notified - The Manila Times
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
30,000-Share Option: Context Therapeutics Grants New Hire Award at $0.97 Exercise Price, 10-year Term - Stock Titan
Context Therapeutics Gains 11%, Insider Trades Reap Benefit - simplywall.st
Is Context Therapeutics Inc. stock in correction or buying zoneWeekly Trade Recap & Free Community Consensus Stock Picks - newser.com
Is Context Therapeutics Inc. showing signs of accumulation2025 Investor Takeaways & Expert Approved Trade Ideas - newser.com
Cantor Fitzgerald Initiates Coverage of Context Therapeutics (CNTX) with Overweight Recommendation - Nasdaq
This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
How Context Therapeutics Inc. stock trades before earningsRate Cut & Reliable Breakout Forecasts - newser.com
What analysts say about Context Therapeutics Inc stockPortfolio Diversification Tips & Tap Into the Fastest-Growing Companies - earlytimes.in
Context Therapeutics Inc (CNTX) 財務データ
収益
当期純利益
現金流量
EPS
2.05%
4.71%
大文字化:
|
ボリューム (24 時間):